Analysis of the mechanism underlying diabetic wound healing acceleration by Calycosin-7-glycoside using network pharmacology and molecular docking

• Published in: Phytomedicine (Stuttgart) Vol. 114; p. 154773
• Main Authors: Chen, Jia, Ma, Huike, Meng, Yujiao, Liu, Qingwu, Wang, Yan, Lin, Yan, Yang, Danyang, Yao, Wentao, Wang, Yazhuo, He, Xiujuan, Li, Ping
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01-06-2023
• Subjects: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Calycosin-7-glucoside; Diabetes Mellitus, Experimental - metabolism; Diabetic wound healing; Glycosides; Interleukin-10; Isoflavones; Macrophage polarization; Mice; Mitochondrial metabolism; Molecular docking; Molecular Docking Simulation; Network Pharmacology; Reactive Oxygen Species; Tumor Necrosis Factor-alpha; Wound Healing; NO; MCP-1; CDKN1B; M-CSF; OXPHOS; mitoOCR; Molecular docking; LPS; IGF1R; Mitochondrial metabolism; CCND1; GM-CSF; Diabetic wound healing; Network pharmacology; STAT6; SKP1; IL; Macrophage polarization; VEGF; Calycosin-7-glucoside; G-CSF; bFGF; AR; CCNE1; AMPK; JC-1
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2023.154773

Diabetic wounds represent a severe clinical challenge in which impaired M2 macrophage polarization and continuous macrophage glycolysis play crucial roles. Calycosin-7-glucoside (CG) is an isoflavone component in Astragali Radix (AR), which has become a research focus for treating diabetic wounds following reports indicating that it has anti-inflammatory effects. However, the mechanism through which CG can treat diabetic wounds is yet to be deciphered.
This study aimed to evaluate the therapeutic effect of CG on diabetic wounds and its underlying mechanism.
The potential mechanism underlying the treatment of diabetic wounds by CG was screened using bioinformatics. The therapeutic effects of CG were then investigated using a db/db diabetic wound model. Moreover, an LPS- and IFN-γ-induced RAW264.7 cell inflammation model was used to elucidate the mechanism underlying the therapeutic effects of CG against diabetic wounds.
Network pharmacology predicted that the AMPK pathway could be the main target through which CG treats diabetic wounds. In db/db diabetic mice, CG could accelerate wound healing and promote granulation tissue regeneration. Protein chip technology revealed that CG increased the production of M-CSF, G-CSF, GM-CSF, IL-10, IL-13, and IL-4 but not that of MCP-1, IL-1β, IL-1α, TNF-α, and TNF-RII. Moreover, CG elevated the proportion of Ly6CLo/- anti-inflammatory monocytes in peripheral blood and M2 macrophages in the wound. The ELISA and flow cytometry analyses revealed that CG enhanced the levels of IL-10, VEGF, CD206, and Arg-1 expression whereas it considerably reduced the levels of IL-1, IL-6, IL-12, TNF-α, CD86, and iNOS expression. Meanwhile, CG increased the macrophage mitochondrial membrane potential and decreased the mitochondrial ADP/ATP ratio and glycolysis rate of M1 macrophages through the ROS/AMPK/STAT6 pathway.
The network pharmacology and molecular dockin identified the AMPK pathway as a critical pathway for treating diabetic wounds using topical CG application. CG was found to promote anti-inflammatory monocyte recruitment and decrease the mitochondrial glycolysis rate to induce M2 macrophage polarization via the ROS/AMPK/STAT6 pathway. These results suggest that CG might be a promising therapeutic agent for diabetic wounds.
[Display omitted]